导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.72% | 4042/4773 |
| 近一周 | -3.49% | 4236/5462 |
| 近一月 | -3.04% | 1522/5421 |
| 近一季 | -7.88% | 2563/5209 |
| 近半年 | -15.64% | 4009/4920 |
| 近一年 | -13.55% | 3612/4366 |
| 近两年 | 28.81% | 2324/2954 |
| 近三年 | 13.79% | 1665/2253 |
| 成立以来 | 39.41% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.72% 2881/4961 |
-15.30% 4650/5312 |
- - |
- - |
| 2025 | 29.46% 1397/4813 |
4.35% 948/3635 |
10.79% 233/4076 |
9.56% 3347/4524 |
2.22% 1038/4813 |
| 2024 | 8.28% 1574/3463 |
0.58% 955/2808 |
7.60% 83/3014 |
2.13% 2931/3129 |
-2.03% 1932/3463 |
| 2023 | -11.08% 1369/2656 |
-0.84% 1830/2280 |
-6.40% 1633/2385 |
-0.86% 458/2515 |
-3.37% 667/2655 |
| 2022 | -8.00% 151/2207 |
5.59% 30/1919 |
-0.71% 1649/2016 |
-21.24% 1899/2113 |
11.42% 145/2208 |
| 2021 | 24.41% 119/1822 |
15.16% 6/1255 |
1.15% 1065/1330 |
11.63% 108/1466 |
-4.32% 1479/1822 |
| 2020 | -9.89% 991/1250 |
-18.43% 1003/1028 |
5.60% 877/1067 |
-2.65% 1077/1164 |
7.46% 710/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 浙商中华预期高股息A VS. 长安沪深300非周期A(740101) |